{
    "pmcid": "8730734",
    "qa_pairs": {
        "How do biparatopic nanobodies enhance their efficacy against SARS-CoV-2?": [
            "By combining two nanobodies targeting different epitopes",
            "By increasing the dosage of a single nanobody",
            "By targeting only the ACE2 receptor",
            "By binding exclusively to the nucleocapsid protein"
        ],
        "What are nanobodies derived from, according to the paper on their therapeutic and diagnostic competency against SARS-CoV-2?": [
            "Camelids and sharks",
            "Mice and rabbits",
            "Humans and primates",
            "Bacteria and yeast"
        ],
        "What is one of the challenges mentioned in the paper regarding the use of nanobodies against SARS-CoV-2 variants?": [
            "Ongoing mutations in the virus necessitate continuous monitoring and adaptation",
            "Nanobodies are too large to penetrate tissues effectively",
            "Nanobodies have high immunogenicity in humans",
            "Nanobodies are difficult to produce in microbial systems"
        ],
        "What is one of the strategies mentioned to extend the half-life of nanobodies due to their rapid renal clearance?": [
            "PEGylation or fusion with Fc domains",
            "Increasing their molecular weight",
            "Administering higher doses",
            "Using oral delivery methods"
        ],
        "Which specific domain of the SARS-CoV-2 virus do nanobodies target to neutralize the virus?": [
            "Receptor-binding domain (RBD) of the spike protein",
            "Nucleocapsid protein",
            "Membrane protein",
            "Envelope protein"
        ]
    }
}